CARR, L. K. Botulinum toxin A should not be first-line therapy for overactivebladder. Canadian Urological Association Journal, [S. l.], v. 5, n. 3, p. 204–9, 2013. DOI: 10.5489/cuaj.643. Disponível em: https://cuaj.ca/index.php/journal/article/view/643. Acesso em: 23 apr. 2024.